lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma

Hideharu Yamada, Masanobu Takahashi, Munenori Watanuki, Mika Watanabe, Sakura Hiraide, Ken Saijo, Keigo Komine, Chikashi Ishioka

Research output: Contribution to journalArticlepeer-review

Abstract

Bone and soft-tissue sarcomas are rare and are highly heterogeneous mesenchymal malignancies. It is there- fore challenging to acquire the clinical data of patients with specific histological subtypes of sarcoma using large clinical trials, and there is a need to further establish the diagnosis and treatment of sarcomas. The results of the current study revealed that long non-coding RNA (lncRNA) highly acceler- ated region 1B (HAR1B) may serve as a predictive biomarker for pazopanib treatment in bone and soft-tissue sarcomas. Using multiplex reverse transcription-quantitative PCR and microarray analyses, the results demonstrated that HAR1B and HOX transcript antisense RNA (HOTAIR) were differentially expressed in pazopanib-sensitive cells and responders. It was further revealed that small interfering RNA-knockdown of HAR1B led to an increased resistance to pazopanib in sarcoma cell lines. Gene expression profiles associated with pazopanib sensitivity included cellular molecular pathways, such as genes involved in von-Willebrand factor-related signaling. The current study demonstrated that lncRNA HAR1B expression in sarcoma cell lines affected cellular sensitivity to pazopanib in patients with sarcoma.

Original languageEnglish
Article number455
JournalOncology Letters
Volume21
Issue number6
DOIs
Publication statusPublished - 2021 Jun

Keywords

  • HOX transcript antisense RNA
  • Highly accelerated region 1B
  • Long non-coding RNA
  • Pazopanib
  • Sarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma'. Together they form a unique fingerprint.

Cite this